Citopcin I.V. Solution bag (Ciprofloxacin)

Overactive bladder

Tegoprazan is a novel patented Potassium-Competitive Acid Blocker (P-CAB) which alleviates the limitations of the historical Proton Pump Inhibitors (PPIs) and of other competing P-CABs. 

Tegoprazan's competitive advantages have been demonstrated via Phase 3 clinical studies conducted in Korea a...

Fixed Dose Combination drug, indicated for Type2 Diabetes with Hyperlipidemia with Clinical trials phase Ⅰ & Ⅲ

Colorectal cancer

Chronic myelogenous leukemia and acute lymphocytic leukemia

Vancomycin-resistantEnterococcus faecium infections

Fixed Dose Combination drug, indicated for Atherosclerosis, thromboembolism

Hepatitis B virus

Anemia of hemodialysis patients with end-stage renal disease

Fixed Dose Combination drug, indicated for Hypertension with Clinical trials phase Ⅰ & Ⅲ

Fixed Dose Combination drug, indicated for Hypertension with dyslipidemia with Clinical trials phase Ⅰ & Ⅲ

- New Chemical Entity with P-CAB(Potassium Competitive Acid Blocker) mechanism
- Already became No.1 A2B product in Korean market since its launch in 2019 and to be expected to achieve $100m sales in Korean domestic market - Medicine indicated for GERD, EE, NERD, GU, H. Pylori- Out licensed to Chin...

Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)